Evidence map›Paper›PMID 34765081›Full record

ArticleMolecular and cellular pharmacology2017

Protein Kinase D: A Potential Therapeutic Target in Prostate Cancer.

Adhiraj Roy, Q Jane Wang

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Potential role for protein kinase D inhibitors in prostate cancer.Journal of molecular medicine (Berlin, Germany) · 2023
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Adhiraj RoyDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Q Jane WangDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
University of Pittsburgh · US

Funding

A novel mitotic regulatory axis in neuroendocrine prostate cancerR01CA229431 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, QIMING JANE · 2019 to 2023
$1.8M
Novel long non-coding RNAs in neuronal survival in focal cerebral ischemiaR21NS096946 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, QIMING JANE · 2016 to 2017
$425k
NCI NIH HHS R01 CA229431NINDS NIH HHS R21 NS096946
6 · The paper itself

Abstract

Protein kinase D (PKD) belongs to a family of serine/threonine kinases in the calcium/calmodulin-dependent kinase superfamily. It modulates a number of signal transduction pathways involved in regulation of cell proliferation, survival, migration, angiogenesis, regulation of gene expression, and protein/membrane trafficking, mediated by variety of stimuli such as growth factors, hormones, and cellular stresses. Although its role in cancer progression remains elusive, current literature supports a potential tumor promoting function of the selective PKD isoforms in prostate cancer, making them promising therapeutic targets for cancer treatment.

Indexed as

Prostate cancerProtein kinase DSignal transductionTherapeutic target

Identifiers

PMID34765081
PMCPMC8580385
OpenAlexW3213499461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.